Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
Inverse dose proportionality: using breakthrough pain medication as a biological indicator for background analgesia escalation.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mercadante Sebastiano, Bellavia Giuseppe Massimo, Napolitano Daniele, Lo Cascio Alessio
Аннотация
OBJECTIVE: To propose a "top-down" pharmacological hypothesis where the effective dose of rapid-onset opioids (ROOs) for breakthrough pain (BTP) serves as a mathematical predictor for required background analgesic adjustments.
METHODS: We analyzed five opioid-tolerant cancer patients in a home-care setting with uncontrolled background pain. Instead of traditional reactive titration, a 1:6 inverse proportionality rule was applied, using the patient-identified effective BTP dose to calculate the new around-the-clock (ATC) dose.
RESULTS: Rapid pain stabilization was achieved in patients within 24-48 h. Despite significant dose escalations (up to 300%), no clinical signs of opioid-induced neurotoxicity or respiratory depression were observed.
CONCLUSION: The effective BTP dose may act as a "bio-indicator" of systemic opioid requirement. This hypothesis challenges the "start low, go slow" dogma, suggesting a more aggressive, patient-centered titration model that warrants formal prospective validation.
METHODS: We analyzed five opioid-tolerant cancer patients in a home-care setting with uncontrolled background pain. Instead of traditional reactive titration, a 1:6 inverse proportionality rule was applied, using the patient-identified effective BTP dose to calculate the new around-the-clock (ATC) dose.
RESULTS: Rapid pain stabilization was achieved in patients within 24-48 h. Despite significant dose escalations (up to 300%), no clinical signs of opioid-induced neurotoxicity or respiratory depression were observed.
CONCLUSION: The effective BTP dose may act as a "bio-indicator" of systemic opioid requirement. This hypothesis challenges the "start low, go slow" dogma, suggesting a more aggressive, patient-centered titration model that warrants formal prospective validation.